BTK and COVID-19: This lead has been followed by other groups that have reported the potential protective effect of acalabrutinib in patients with lymphoproliferative disorders affected by severe forms of COVID-19 (19) and by the initiation of clinical trials with BTK inhibitors in patients with severe COVID-19.